Description: Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.
Home Page: www.cellectis.com
CLLS Technical Analysis
8, rue de la Croix Jarry
Paris,
75013
France
Phone:
33 1 81 69 16 00
Officers
| Name | Title |
|---|---|
| Dr. Andre Choulika Ph.D. | Co-Founder, CEO & Director |
| Dr. David J. D. Sourdive Ph.D. | Director, Deputy CEO, Exec. VP of CMC and Manufacturing |
| Dr. Bing C. Wang M.B.A., Ph.D. | Chief Financial Officer |
| Valerie Cros | Principal Financial Officer & Principal Accounting Officer |
| Mr. Jean Charles Epinat | Chief Technological Officer |
| Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer |
| Mr. Stephan Reynier M.Sc., MSc | Chief Regulatory & Pharmaceutical Compliance Officer |
| Ms. Marie-Bleuenn Terrier | Gen. Counsel & Sec. of the Board of Directors |
| Pascalyne Wilson | Director of Communications |
| Ms. Kyung Nam-Wortman | Exec. VP & Chief HR Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7503 |
| Price-to-Sales TTM: | 4.4785 |
| IPO Date: | 2007-02-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 294 |